Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Inclusion Criteria:

Eastern Collaborative Oncology Group (ECOG) performance score of less than or equal to 2.
Documented relapsed or progressive Multiple Myeloma (MM) on or after any regimen or is refractory to the most recent line of therapy.
Positive for translocation t(11;14) as determined by an analytically validated Fluorescent In Situ Hybridization (FISH) assay per central laboratory testing.
Received prior treatment with at least 1 prior line of therapy for MM.
Measurable disease on Screening per International Myeloma Working Group (IMWG) criteria.
Meets absolute neutrophil count, platelet count, hemoglobin, liver and kidney function laboratory values within 2 weeks prior to first dose of study drug.

Exclusion Criteria:

Has a pre-existing condition that is contraindicated including.

Non-secretory or oligo-secretory MM
Active plasma cell leukemia.
Waldenström's macroglobulinemia.
Primary amyloidosis.
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
Active hepatitis B or C infection based on screening blood testing.
Known active Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Significant cardiovascular disease.
Major surgery within 4 weeks prior to first dose.
Acute infections requiring antibiotic, antifungal or antiviral therapy within14 days prior to first dose.
Peripheral neuropathy ≥ Grade 3 or ≥ Grade 2 with pain within 2 weeks prior to first dose.
Uncontrolled diabetes or uncontrolled hypertension within 14 days prior to first dose.
Any other medical condition that, in the opinion of the Investigator, would adversely affect the participant's participation in the study.
History of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry Other protocol defined inclusion/exclusion criteria could apply